The Association Between Pancreatic Steatosis and Metabolic Syndrome

Objectives To date, the complete natural history of pancreatic steatosis is unknown. This study aimed to investigate the association of fatty pancreas (FP) in the incidence of metabolic syndrome and its components among Chinese patients with a 5-year follow-up. Methods Three independent cross-sectional surveys were carried out in 2013, 2015, and 2018. Fatty pancreas was diagnosed via transabdominal sonography. Logistic regression analysis was used to estimate the correlation between FP and metabolic syndrome. New cases of metabolic syndrome and its components were estimated by Cox proportional hazards models. Results At baseline, 12,551 individuals classified into FP (n = 1010) and non-FP (n = 11,541) groups were finally enrolled. In cross-sectional analyses, odds ratio of FP was 2.378 (95% confidence interval [CI], 2.085–2.713; P < 0.001). In longitudinal analyses, FP was associated with the occurrence of metabolic syndrome (hazard ratio [HR], 3.179; 95% CI, 2.197–4.6; P < 0.001), type 2 diabetes mellitus (HR, 13.99; 95% CI, 7.865–24.883; P < 0.001), nonalcoholic fatty liver disease (HR, 31.843; 95% CI, 7.73–131.171; P < 0.001), and hypertension (HR, 12.801; 95% CI, 7.323–22.38; P < 0.001). Conclusions Pancreatic steatosis is strongly associated with the occurrence of metabolic syndrome and its components such as hypertension and diabetes.